Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Dimension Therapeutics will work with Bayer HealthCare to develop a gene therapy for the treatment of hemophilia A based on Dimension’s adeno-associated virus technology. Dimension says its technology delivers the clotting factor gene, resulting in long-lasting expression of blood-clotting protein. Dimension, based in Cambridge, Mass., will receive $20 million up front from Bayer and could get milestone payments of up to $232 million. Separately, Dimension closed a financing round in which it raised $30 million.
This article has been sent to the following recipient: